These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 21170648)

  • 1. Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC).
    Cho EY; Chang MH; Choi YL; Lee JE; Nam SJ; Yang JH; Park YH; Ahn JS; Im YH
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):753-61. PubMed ID: 21170648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.
    Toyama T; Yamashita H; Kondo N; Okuda K; Takahashi S; Sasaki H; Sugiura H; Iwase H; Fujii Y
    BMC Cancer; 2008 Oct; 8():309. PubMed ID: 18950515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.
    Rhee J; Han SW; Oh DY; Kim JH; Im SA; Han W; Park IA; Noh DY; Bang YJ; Kim TY
    BMC Cancer; 2008 Oct; 8():307. PubMed ID: 18947390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
    Derin D; Eralp Y; Ozluk Y; Yavuz E; Guney N; Saip P; Igci A; Ozmen V; Kücücük S; Aslay I; Aydiner A; Topuz E
    Cancer Invest; 2008 Aug; 26(7):671-9. PubMed ID: 18608215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone.
    Yovino S; Kwok Y; Krasna M; Bangalore M; Suntharalingam M
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1438-43. PubMed ID: 16029805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic study associated with long-term survival in Japanese patients with node-negative breast cancer.
    Kato T; Kimura T; Miyakawa R; Fujii A; Yamamoto K; Kameoka S; Nishikawa T; Kasajima T
    Br J Cancer; 2000 Jan; 82(2):404-11. PubMed ID: 10646896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: A new independent prognostic marker in primary breast cancer.
    Scorilas A; Talieri M; Ardavanis A; Courtis N; Dimitriadis E; Yotis J; Tsiapalis CM; Trangas T
    Cancer Res; 2000 Oct; 60(19):5427-33. PubMed ID: 11034084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival.
    Lee JA; Kim KI; Bae JW; Jung YH; An H; Lee ES;
    Breast Cancer Res Treat; 2010 Aug; 123(1):177-87. PubMed ID: 20574671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
    Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
    Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer?
    Parker CC; Ampil F; Burton G; Li BD; Chu QD
    Surgery; 2010 Aug; 148(2):386-91. PubMed ID: 20580045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer.
    Nogi H; Kobayashi T; Suzuki M; Tabei I; Kawase K; Toriumi Y; Fukushima H; Uchida K
    Oncol Rep; 2009 Feb; 21(2):413-7. PubMed ID: 19148516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of Lewis X is associated with poor prognosis in triple-negative breast cancer.
    Koh YW; Lee HJ; Ahn JH; Lee JW; Gong G
    Am J Clin Pathol; 2013 Jun; 139(6):746-53. PubMed ID: 23690116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclooxygenase-2 expression in postmastectomy chest wall relapse.
    Kim JH; Bossuyt V; Ponn T; Lannin D; Haffty BG
    Clin Cancer Res; 2005 Jul; 11(14):5199-205. PubMed ID: 16033837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initially metastatic breast carcinoma has a distinct disease pattern but an equivalent outcome compared with recurrent metastatic breast carcinoma.
    Jimeno A; Amador ML; González-Cortijo L; Tornamira MV; Ropero S; Valentín V; Hornedo J; Cortés-Funes H; Colomer R
    Cancer; 2004 May; 100(9):1833-42. PubMed ID: 15112263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.
    Haffty BG; Yang Q; Reiss M; Kearney T; Higgins SA; Weidhaas J; Harris L; Hait W; Toppmeyer D
    J Clin Oncol; 2006 Dec; 24(36):5652-7. PubMed ID: 17116942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery.
    Galizia G; Lieto E; Ferraraccio F; De Vita F; Castellano P; Orditura M; Imperatore V; La Mura A; La Manna G; Pinto M; Catalano G; Pignatelli C; Ciardiello F
    Ann Surg Oncol; 2006 Jun; 13(6):823-35. PubMed ID: 16614884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.